Volume 14 Issue 3
May  2023
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2023  >  14(3): 389-396
Wang Zipei, Guo Hui, Zhang Bo, et al. Clinicopathological features and prognostic analysis of 44 patients with polyomavirus nephropathy after kidney transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(3): 389-396. doi: 10.3969/j.issn.1674-7445.2023.03.010
Citation: Wang Zipei, Guo Hui, Zhang Bo, et al. Clinicopathological features and prognostic analysis of 44 patients with polyomavirus nephropathy after kidney transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(3): 389-396. doi: 10.3969/j.issn.1674-7445.2023.03.010
shu

Clinicopathological features and prognostic analysis of 44 patients with polyomavirus nephropathy after kidney transplantation

doi: 10.3969/j.issn.1674-7445.2023.03.010

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation of Ministry of Education, Key Laboratory of Organ Transplantation of National Health Commission, Key Laboratory of Organ Transplantation of Chinese Academy of Medical Sciences, Wuhan 430030, China

More Information
  • Corresponding author: Du Dunfeng, Email: dfdu@tjh.tjmu.edu.cn
  • Received Date: 2023-01-06
  • Publish Date: 2023-05-15
    Abstract
  •   Objective  To analyze the clinicopathological features and prognosis of polyomavirus nephropathy (PyVN) after kidney transplantation.  Methods  Clinical data of 44 patients who were diagnosed with PyVN after kidney transplantation were retrospectively analyzed. The causes of puncture and the time of pathological diagnosis were analyzed. Histological grading was carried out according to Banff 2018 classification. Clinical data and pathological characteristics of patients at all grades were statistically compared. BK viral DNA loads in the blood and urine were measured and renal allograft function were assessed. Clinical prognosis of all patients was compared among different groups and the risk factors affecting clinical prognosis were also analyzed.  Results  The time interval between pathological diagnosis of PyVN and kidney transplantation was 16(8, 29) months, and the increase of serum creatinine level was the main cause for puncture. Among 44 patients, 19 cases were classified as grade ⅠPyVN, 21 cases of grade Ⅱ PyVN and 4 cases of grade Ⅲ PyVN, respectively. Under optical microscope, there was no significant difference in the positive rate of virus inclusion bodies among different groups (P=0.148). Inflammatory cell infiltration, interstitial fibrosis and polyomavirus load in grade Ⅱ PyVN patients were all more or higher than those in grade Ⅰ counterparts. Inflammatory cell infiltration and polyomavirus load in grade Ⅲ patients were more or higher than those in grade Ⅰ counterparts. Polyomavirus load in grade Ⅲ patients was more or higher than that in grade Ⅱ counterparts. The differences were statistically significant (all P < 0.05/3). Upon diagnosis, BK viral DNA load was detected in the blood and urine of 39 patients. Among them, 38 patients were positive for BK virus in the urine and 30 patients were positive for BK virus in the blood. The serum creatinine level upon diagnosis was higher compared with that at postoperative 1 month. The serum creatinine level at the final follow-up was significantly higher than that upon diagnosis. The differences were statistically significant (P < 0.001, P=0.049). There was no significant difference in the serum creatinine level among patients with different grades of PyVN at postoperative 1 month (P=0.554). The serum creatinine level of patients with grade Ⅱ PyVN upon diagnosis was significantly higher than that of those with grade Ⅰ PyVN (P=0.007). The 1-, 3- and 5-year cumulative survival rates of renal allografts were 95%, 69% and 62%, respectively. The survival rates of renal allografts significantly differed among patients with different grades of PyVN. The higher the grade, the lower the survival rate (P=0.014). Univariate and multivariate Cox's regression analyses prompted that intrarenal polyomavirus load and serum creatinine level upon diagnosis were the independent risk factors for renal allograft dysfunction (all P < 0.05).  Conclusions  PyVN mainly occurs within 2 years after kidney transplantation. Clinical manifestations mainly consist of increased serum creatinine level, BK viremia and BK viruria. Postoperative routine monitoring of BK virus contributes to early diagnosis and protection of renal allografts. Banff 2018 classification may effectively predict the prognosis of renal allografts.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    KOTLA SK, KADAMBI PV, HENDRICKS AR, et al. BK polyomavirus-pathogen, paradigm and puzzle[J]. Nephrol Dial Transplant, 2021, 36(4): 587-593. DOI: 10.1093/ndt/gfz273.
    [2]
    URBANO PRP, NALI LHDS, OLIVEIRA RDR, et al. Variable sources of BK virus in renal allograft recipients[J]. J Med Virol, 2019, 91(6): 1136-1141. DOI: 10.1002/jmv.25409.
    [3]
    KANT S, DASGUPTA A, BAGNASCO S, et al. BK virus nephropathy in kidney transplantation: a state-of-the-art review[J]. Viruses, 2022, 14(8): 1616. DOI: 10.3390/v14081616.
    [4]
    SHEN CL, WU BS, LIEN TJ, et al. BK polyomavirus nephropathy in kidney transplantation: balancing rejection and infection[J]. Viruses, 2021, 13(3): 487. DOI: 10.3390/v13030487.
    [5]
    HIRSCH HH, RANDHAWA PS, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13528. DOI: 10.1111/ctr.13528.
    [6]
    IMLAY H, BAUM P, BRENNAN DC, et al. Consensus definitions of BK polyomavirus nephropathy in renal transplant recipients for clinical trials[J]. Clin Infect Dis, 2022, 75(7): 1210-1216. DOI: 10.1093/cid/ciac071.
    [7]
    AMBALATHINGAL GR, FRANCIS RS, SMYTH MJ, et al. BK polyomavirus: clinical aspects, immune regulation, and emerging therapies[J]. Clin Microbiol Rev, 2017, 30(2): 503-528. DOI: 10.1128/CMR.00074-16.
    [8]
    HIRSCH HH, RANDHAWA P, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4): 179-188. DOI: 10.1111/ajt.12110.
    [9]
    CHONG S, ANTONI M, MACDONALD A, et al. BK virus: current understanding of pathogenicity and clinical disease in transplantation[J]. Rev Med Virol, 2019, 29(4): e2044. DOI: 10.1002/rmv.2044.
    [10]
    SAWINSKI D, TROFE-CLARK J. BK virus nephropathy[J]. Clin J Am Soc Nephrol, 2018, 13(12): 1893-1896. DOI: 10.2215/CJN.04080318.
    [11]
    FURMAGA J, KOWALCZYK M, ZAPOLSKI T, et al. BK polyomavirus-biology, genomic variation and diagnosis[J]. Viruses, 2021, 13(8): 1502. DOI: 10.3390/v13081502.
    [12]
    NICKELEIT V, SINGH HK, RANDHAWA P, et al. The Banff Working Group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations[J]. J Am Soc Nephrol, 2018, 29(2): 680-693. DOI: 10.1681/ASN.2017050477.
    [13]
    WANG M, ZHOU Q, WANG H, et al. An application of the 2018 Banff classification for BK polyomavirus-associated nephropathy in renal transplantation[J]. Transpl Infect Dis, 2021, 23(3): e13557. DOI: 10.1111/tid.13557.
    [14]
    KOWALEWSKA J, EL MOUDDEN I, PERKOWSKA-PTASINSKA A, et al. Assessment of the Banff Working Group classification of definitive BK polyomavirus nephropathy[J]. Transpl Int, 2021, 34(11): 2286-2296. DOI: 10.1111/tri.14003.
    [15]
    NICKELEIT V, SINGH HK, DADHANIA D, et al. The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: a multicenter validation study in the modern era[J]. Am J Transplant, 2021, 21(2): 669-680. DOI: 10.1111/ajt.16189.
    [16]
    NANKIVELL BJ, RENTHAWA J, SHINGDE M, et al. The importance of kidney medullary tissue for the accurate diagnosis of BK virus allograft nephropathy[J]. Clin J Am Soc Nephrol, 2020, 15(7): 1015-1023. DOI: 10.2215/CJN.13611119.
    [17]
    NICKELEIT V, SINGH HK. Polyomaviruses and disease: is there more to know than viremia and viruria? [J]. Curr Opin Organ Transplant, 2015, 20(3): 348-358. DOI: 10.1097/MOT.0000000000000192.
    [18]
    NICKELEIT V, DAVIS VG, THOMPSON B, et al. The urinary polyomavirus-haufen test: a highly predictive non-invasive biomarker to distinguish "presumptive" from "definitive" polyomavirus nephropathy: how to use it-when to use it-how does it compare to PCR based assays? [J]. Viruses, 2021, 13(1): 135. DOI: 10.3390/v13010135.
    [19]
    WIEGLEY N, WALAVALKAR V, AUJLA H, et al. Clinicopathologic characteristics of JC virus nephropathy in kidney transplant recipients[J]. Transplantation, 2021, 105(5): 1069-1076. DOI: 10.1097/TP.0000000000003363.
    [20]
    DUMOULIN A, HIRSCH HH. Reevaluating and optimizing polyomavirus BK and JC real-time PCR assays to detect rare sequence polymorphisms[J]. J Clin Microbiol, 2011, 49(4): 1382-1388. DOI: 10.1128/JCM.02008-10.
    [21]
    SHANMUGHAM S, BHADAURIA D, AGRAWAL V, et al. The diagnostic and therapeutic dilemma of the co-existence of BK virus nephropathy with acute rejection - an experience from a single centre and review of the literature[J]. Transpl Immunol, 2022, 72: 101581. DOI: 10.1016/j.trim.2022.101581.
    [22]
    KOMORNICZAK M, KRÓL E, LIZAKOWSKI S, et al. Screening for polyomavirus viruria like early detection of human polyomavirus infection and replication: the results of a single-center observation[J]. Transplant Proc, 2022, 54(4): 989-994. DOI: 10.1016/j.transproceed.2022.02.039.
    [23]
    CHEN XT, YANG SC, LI J, et al. Prognosis of BK polyomavirus nephropathy: 10-year analysis of 133 renal transplant recipients at a single center[J]. Chin Med J (Engl), 2019, 132(4): 388-394. DOI: 10.1097/CM9.0000000000000085.
    [24]
    KREJČÍ K, TICHÝ T, BEDNAŘÍKOVÁ J, et al. Nephrotoxicity of calcineurin inhibitors as a risk factor for BK polyomavirus replication after kidney transplantation[J]. J Med Virol, 2021, 93(6): 3871-3879. DOI: 10.1002/jmv.26520.
    [25]
    HOD-DVORAI R, LEE R, MULUHNGWI P, et al. Development of de novo donor-specific antibodies in renal transplant recipients with BK viremia managed with immunosuppression reduction[J]. Transpl Infect Dis, 2023, 25(1): e13993. DOI: 10.1111/tid.13993.
    [26]
    MYINT TM, CHONG CHY, WYLD M, et al. Polyoma BK virus in kidney transplant recipients: screening, monitoring, and management[J]. Transplantation, 2022, 106(1): e76-e89. DOI: 10.1097/TP.0000000000003801.
    [27]
    HIRSCH HH, MENGEL M, KAMAR N. BK polyomavirus consensus[J]. Clin Infect Dis, 2022, 75(11): 2046-2047. DOI: 10.1093/cid/ciac594.
    [28]
    MALIK O, SALEH S, SULEIMAN B, et al. Prevalence, risk factors, treatment, and overall impact of BK viremia on kidney transplantation[J]. Transplant Proc, 2019, 51(6): 1801-1809. DOI: 10.1016/j.transproceed.2019.03.035.
    [29]
    REISCHIG T, KACER M, HES O, et al. Viral load and duration of BK polyomavirus viraemia determine renal graft fibrosis progression: histologic evaluation of late protocol biopsies[J]. Nephrol Dial Transplant, 2019, 34(11): 1970-1978. DOI: 10.1093/ndt/gfz061.
    [30]
    SUBRAMANIAN KS, SRINIVAS BH, NACHIAPPA GANESH R, et al. Revisit of polyomavirus nephropathy grading in renal allograft recipients according to the Banff 2019 Working Group classification: a study from a large transplant center in South India[J]. Cureus, 2022, 14(2): e22377. DOI: 10.7759/cureus.22377.
    [31]
    NILI F, KHATAMI SM, SABERAFSHARIAN M, et al. Challenging issues in diagnosis and screening of BK virus nephropathy in kidney transplant recipients, a multicenter experience in Iranian population[J]. Iran J Kidney Dis, 2022, 16(6): 368-373.
    [32]
    HIRSCH HH, STEIGER J. Polyomavirus BK[J]. Lancet Infect Dis, 2003, 3(10): 611-623. DOI: 10.1016/s1473-3099(03)00770-9.
    [33]
    B KOPP J. Banff classification of polyomavirus nephropathy: a new tool for research and clinical practice[J]. J Am Soc Nephrol, 2018, 29(2): 354-355. DOI: 10.1681/ASN.2017121328.
    [34]
    BORRIELLO M, INGROSSO D, PERNA AF, et al. BK virus infection and BK-virus-associated nephropathy in renal transplant recipients[J]. Genes (Basel), 2022, 13(7): 1290. DOI: 10.3390/genes13071290.
    [35]
    MASUTANI K, SHAPIRO R, BASU A, et al. The Banff 2009 Working Proposal for polyomavirus nephropathy: a critical evaluation of its utility as a determinant of clinical outcome[J]. Am J Transplant, 2012, 12(4): 907-918. DOI: 10.1111/j.1600-6143.2012.03993.x.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (200) PDF downloads(76) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return